Therapy should be individualized: RAAS blockade and optimal blood pressure management for all, augmented by glycemic control and disease-modifying agents such as SGLT2 inhibitors or finerenone in confirmed diabetic kidney disease. This evidence concerns the gene SLC5A2 and diabetic kidney disease.